

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of the Claims:**

1-63. (canceled)

64. (Currently amended) A multispecific antibody comprising four polypeptides, wherein a first and a second of said polypeptides each comprise a heavy chain constant domain and a heavy chain variable domain, and a third and a fourth of said polypeptides are each common light chains that are identical to each other, wherein said first polypeptide and said third polypeptide form a binding domain that binds a first antigen, and wherein said second polypeptide and said fourth polypeptide form a binding domain that binds a different antigen, and wherein said first polypeptide and said second polypeptide dimerize to form a multispecific antibody, wherein the multispecific antibody is an IgG, IgE or IgD antibody.

65. (Previously presented) The multispecific antibody of claim 64, wherein the first polypeptide further comprises a first multimerization domain, and the second polypeptide further comprises a second multimerization domain, and wherein the first and second polypeptides dimerize by interaction of the first and second multimerization domains to form a multispecific antibody.

66. (Previously presented) The multispecific antibody of claim 65, wherein the multimerization domains of the first and second polypeptide interact at an amino acid side chain protuberance of one of the first and second polypeptides and an amino acid side chain cavity of the other polypeptide.

67. (Previously presented) The multispecific antibody of claim 65, further comprising a non-naturally occurring disulfide bond between the first and second polypeptide.

68. (Previously presented) The multispecific antibody of claim 67, wherein the multimerization domain is at least a part of a C<sub>H</sub>3 domain region of an antibody constant

domain, and the non-naturally occurring disulfide bond is between the C<sub>H</sub>3 multimerization domains of the first and second polypeptides.

69. (Previously presented) A composition comprising the multispecific antibody of claim 64 and a carrier.

70. (Currently amended) A multispecific antibody comprising two heteromeric polypeptides and two light chains wherein:

(a) the first heteromeric polypeptide comprises a first heavy chain variable domain and a first multimerization domain; and

(b) the second heteromeric polypeptide comprises a second heavy chain variable domain and a second multimerization domain; and wherein the two light chains have an amino acid sequence identity of 100%, and the first and second heteromeric polypeptides dimerize by interaction of the first and second multimerization domains to form a multispecific antibody, wherein the multispecific antibody is an IgG, IgE or IgD antibody.

71. (Canceled)

72. (Canceled)

73. (Previously presented) The multispecific antibody of claim 70, wherein the first multimerization domain has a protuberance and the second multimerization domain has a cavity, and wherein the protuberance is positionable in the cavity.

74. (Previously presented) The multispecific antibody of claim 70, further comprising a non-naturally occurring disulfide bond between the first and second heteromeric polypeptides.

75. (Previously presented) The multispecific antibody of claim 74, wherein the multimerization domains comprise a part of a C<sub>H</sub>3 domain of an antibody constant domain, and the non-naturally occurring disulfide bond is between the C<sub>H</sub>3 multimerization domains of the first and second heteromeric polypeptides.

76. (Previously presented) A composition comprising the multispecific antibody of claim 70 and a carrier.

77. (Previously presented) The multispecific antibody of claim 73 further comprising a non-naturally occurring disulfide bond between the first and second heteromeric polypeptides.